KRAS and non-small cell lung carcinoma: Similarly, the adoption of front-line pembrolizumab in PD-L1 positive advanced stage NSCLC patients harboring a KRAS exon 2 p.G12C point mutation seemed to be predictive of higher objective response rate (ORR, 57% versus 29%), median progression free survival (PFS, 12 versus 6 months) and OS (28 versus 15 months) [44].